Assessing the clinical benefit of nuclear matrix protein 22 in the surveillance of patients with nonmuscle-invasive bladder cancer and negative cytology Academic Article uri icon

Overview

MeSH Major

  • Biomarkers, Tumor
  • Nuclear Proteins
  • Urinary Bladder Neoplasms

abstract

  • For clinicians who would perform a cystoscopy at a threshold of 5% for recurrence or 1% for progression, NMP22 did not aid clinical decision-making. For less risk-averse clinicians who would only perform a cystoscopy at a threshold probability >thinsp;8% for recurrence or > 3% for progression, NMP22 helped to indicate which patients required cystoscopy and which could be spared this procedure.

publication date

  • July 2011

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3334293

Digital Object Identifier (DOI)

  • 10.1002/cncr.25903

PubMed ID

  • 21692050

Additional Document Info

start page

  • 2892

end page

  • 7

volume

  • 117

number

  • 13